Resolutions from the Annual General Meeting of Novo Nordisk A/S
25 March 2022 - 1:55AM
Resolutions from the Annual General Meeting of Novo Nordisk A/S
Bagsværd, Denmark, 24
March 2022 -
Today, Novo Nordisk A/S held its Annual General Meeting.
At the Annual General Meeting, Helge Lund, chair of the Board of
Directors communicated: “Novo Nordisk made good progress in the
past year and exceeded expectations with strong financial
performance. We broadened our technology platforms and product
pipeline to strengthen the basis for long-term growth, whilst
investing significantly in expanding our future production
capacity. Our long-standing aspiration of creating value for
society is more relevant than ever, and we continue to serve more
patients in need around the world in line with our purpose of
driving change in diabetes and other serious chronic disease.”
Resolutions adopted at the Annual General
MeetingFinancial year
2021 and board
remuneration
- Approval of the Company’s statutory
Annual Report 2021 and distribution of profits according to the
statutory Annual Report 2020.
- The final dividend for 2021 of DKK
6.90 for each Novo Nordisk A or B share of DKK 0.20. The total
dividend for 2021 of DKK 10.40 includes both the interim dividend
of DKK 3.50 for each Novo Nordisk A and B share of DKK 0.20 which
was paid in August 2021 and the final dividend of DKK 6.90 for each
Novo Nordisk A and B share of DKK 0.20 to be paid in March 2022.
T
- The actual remuneration of the
Board of Directors for 2021 and the remuneration level for 2022
were approved.
- The Remuneration Report 2021 was
approved (advisory vote).
Elections
- Re-election of Helge Lund as chair
of the Board of Directors.
- Election of Henrik Poulsen as vice
chair of the Board of Directors.
- Re-election of Jeppe Christiansen,
Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Kasim Kutay and
Martin Mackay as members of the Board of Directors.
- Election of Christina Law as new
member of the Board of Directors.
- Re-appointment of Deloitte
Statsautoriseret Revisionspartnerselskab as the Company’s
auditor.
Shares and capital
- Reduction of the Company’s B share
capital by cancellation of part of the Company’s own holding of B
shares. The Company’s B share capital is reduced by DKK 6,000,000
from DKK 354,512,800 to DKK 348,512,800. The Company’s A share
capital of DKK 107,487,200 remains unchanged, whereby the Company’s
share capital will amount to DKK 456,000,000.
- Authorisation to the Board of
Directors until the Annual General Meeting 2023 to allow the
Company to repurchase own shares of up to 10% of the share capital
subject to a holding limit of 10% of the share capital.
- Extension of the authorisation to the Board of Directors to
increase the Company's share capital for a period of one year until
24 March 2024 up to nominally DKK 45,600,000.
Other
- Amendments to the Remuneration
Policy regarding payment of contribution to social security taxes
imposed by foreign authorities outside the EU and regarding
severance payment.
- Amendment to the Articles of
Association regarding removal of age limit on candidates standing
for election to the Board of Directors.
The meeting was held as a partially electronic meeting enabling
shareholders to participate either in person or virtually. The
shareholders had been encouraged to exercise their rights by
submitting proxies or votes by correspondence in advance of the
Annual General Meeting.
Composition of the Board of Directors and its
committeesIn February 2022, Novo Nordisk employees in
Denmark elected four board members, Elisabeth Dahl Christensen,
Liselotte Hyveled, Mette Bøjer Jensen and Thomas Rantzau for a
period of four years following the Annual General Meeting 2022.
After the Annual General Meeting, the Board of Directors held a
board meeting to appoint members of its committees.
The Board of Directors, including its committees, is now
composed as follows:
- Helge Lund (chair of the Board and
chair of the Nomination Committee)
- Henrik Poulsen (vice chair of the
Board, member of the Audit Committee and the Remuneration
Committee)
- Elisabeth Dahl Christensen
(employee representative and member of the Remuneration
Committee)
- Jeppe Christiansen (chair of the
Remuneration Committee)
- Laurence Debroux (chair of the
Audit Committee and member of the Remuneration Committee)
- Andreas Fibig (member of the
Research & Development Committee)
- Sylvie Grégoire (member of the
Audit Committee, the Nomination Committee and the Research &
Development Committee)
- Liselotte Hyveled (employee
representative and member of the Research & Development
Committee)
- Mette Bøjer Jensen (employee
representative and member of the Audit Committee)
- Kasim Kutay (member of the
Nomination Committee and the Research & Development
Committee)
- Christina Law (member of the Audit
Committee)
- Martin Mackay (chair of the
Research & Development Committee and member of the Remuneration
Committee)
- Thomas Rantzau (employee
representative and member of the Nomination Committee)
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat diabetes and other serious chronic diseases such as
obesity and rare blood and endocrine disorders. We do so by
pioneering scientific breakthroughs, expanding access to our
medicines and working to prevent and ultimately cure disease. Novo
Nordisk employs about 47,800 people in 80 countries and markets its
products in around 170 countries. Novo Nordisk's B shares are
listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the
New York Stock Exchange (NVO). For more information, visit
novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Further information
Media: |
|
|
Ambre Brown
Morley |
+45 3079 9289 |
abmo@novonordisk.com |
Michael Bachner
(US) |
+1 609 664
7308 |
mzyb@novonordisk.com |
|
|
|
Investors: |
|
|
Daniel Muusmann
Bohsen |
+45 3075 2175 |
dabo@novonordisk.com |
Ann Søndermølle
Rendbæk |
+45 3075 2253 |
arnd@novonordisk.com |
David Heiberg
Landsted |
+45 3077 6915 |
dhel@novonordisk.com |
Jacob Martin
Wiborg Rode |
+45 3075 5956 |
jrde@novonordisk.com |
Mark Joseph
Root |
+1 848 213
3219 |
mjhr@novonordisk.com |
Company announcement No 25 / 2022
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From May 2024 to Jul 2024
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jul 2023 to Jul 2024